29 June 2026

Australian Securities Exchange
20 Bridge Street
Sydney NSW 2000

Investor Roadshow Presentation

Melbourne, Victoria | Alcidion Group Limited (ASX:ALC) ('**Alcidion**' or the '**Company**') is pleased to announce that its Group Managing Director and CEO, Kate Quirke, will undertake a non-deal investor roadshow in Singapore and Hong Kong commencing 29 June 2026.

The roadshow is intended to introduce Alcidion to potential new investors and will be supported by the attached investor presentation.

The roadshow is being managed by Spark Plus.

ENDS

Authorised for ASX release by the Board of Alcidion Group Limited.

For further information, please contact: investor@alcidion.com

About Alcidion

Alcidion Group Limited (Alcidion) has a simple purpose: to transform healthcare with proactive, smart, intuitive technology solutions that improve the efficiency and quality of patient care in healthcare organisations worldwide.

Alcidion offers a complementary set of software products and technical services that create a unique offering in the global healthcare market. Based on the flagship product, Miya Precision, the solutions aggregate meaningful information to centralised dashboards, support interoperability, facilitate communication and task management in clinical and operational settings and deliver clinical decision support at the point of care; all in support of Alcidion's mission to improve patient outcomes.

Since listing on the ASX in 2016, Alcidion has acquired multiple healthcare IT companies and now operates across three established markets — Australia, New Zealand and the United Kingdom — serving hospitals and healthcare organisations at scale, with further geographical expansion planned.

With over 25 years of healthcare experience, Alcidion brings together the very best in technology and market knowledge to deliver solutions that make healthcare better for everyone.

www.alcidion.com

ALCIDION

Roadshow Investor Presentation

June 2026

Disclaimer

The information contained in this document ("Document") has been prepared by Alcidion Group Limited ACN 143 142 410 (referred to as "Alcidion" or "Company"). This Document is current as at the date of this Document and should be read in conjunction with other Alcidion periodic and continuous disclosure announcements filed with the Australian Securities Exchange (ASX), available at www.asx.com.au.

The information in this Document is not intended to form the basis of any investment decision in relation to the Company or its assets and should not be considered as a recommendation to the Recipient to acquire securities in the Company. This Document is not a prospectus, profile statement or disclosure document and does not constitute an offer or invitation to acquire securities or otherwise invest in the Company, and no agreement to subscribe for securities will be entered into on the basis of this Document.

No representation or warranty, expressed or implied, is or will be made, and no responsibility or liability is or will be accepted by the Company, any of their respective officers, servants, agents or advisers (collectively "Limited Parties") as to or in relation to the accuracy, reasonableness, completeness or reliability of the information in this Document or any other written or oral information made available to any Recipients or their advisers. Any liability therefore is hereby expressly disclaimed. In particular, no representation or warranty is given as to the achievability or reasonableness of any future projections, management estimates or plans, prospects, returns or forecasts.

To the fullest extent permitted by law, the Limited Parties will not have any responsibility or liability for any loss or damage (whether foreseeable or not), however arising (including as a result of negligence), in relation to or in connection with the provision of this Document, the Recipient's or any other person's purported reliance on this Document, the failure to provide information of which any of the Limited Parties becomes aware or any errors in or omissions from this Document.

None of the Limited Parties makes or gives any representation, warranty or guarantee, express or implied, that the information in this Document is accurate, current, reliable or complete, has been or will be audited or independently verified, or that reasonable care has been taken in compiling, preparing or furnishing it. Various statements in this Document constitute statements relating to intentions, future acts and events including forecast financial information ("Forward Looking Statements"). Forward Looking Statements involve subjective judgment and analysis, known and unknown risks, uncertainties and other important factors that may cause those future acts, events and circumstances to differ from the way or manner in which they are expressly or impliedly portrayed herein. The Limited Parties do not make or give any representation, warranty or guarantee, express or implied, that any Forward Looking Statements will be achieved or proven correct, or that any assumptions or projections on which the Forward Looking Statements are based are reasonable. No historical financial information, forecast financial information, estimates or projections contained in this Document or any other financial information derived from that information, can be relied upon as a promise or representation, as to the past, present or the future. Past performance is not necessarily a guide to future likelihood of achievement or reasonableness of any Forward Looking Statement, forecast financial information or other forecast.

The Limited Parties do not undertake any obligation to (and expressly disclaim any obligation to) provide the Recipients with access to any additional information or to correct any inaccuracies herein which may become apparent or to disseminate any updates or revisions to any Forward Looking Statements in this Document to reflect any change in expectations in relation to any such statements or any change in events, conditions or circumstances on which any such statement is based.

This document also contains statistics, data and other information relating to markets, market sizes, market shares, market positions and other industry data pertaining to the Alcidion's business and markets. Such information is generally based on independent market and industry data or research. The Alcidion has not independently verified, and cannot give any assurances as to the accuracy and completeness of the information sourced from market and industry data or research contained herein. Accordingly, the accuracy and completeness of such information is not guaranteed. There is no assurance that any of the forecasts or projections contained in the independent market and industry data or research will be achieved. Forecasts and projections involve risks and uncertainties and are subject to change based on various factors. You should note that market data and statistics are inherently predictive and subject to uncertainty and not necessarily reflective of actual market conditions.

Neither the receipt of this Document by any person nor any information contained in it or supplied with it or subsequently communicated to any person in connection with a proposed investment in the Company constitutes, or is to be taken as constituting, the giving of investment or financial product advice (or any other advice) to any such person. Each such person should make their own independent assessment of the merits or otherwise of investing in the Company and should seek their own professional advice in respect of any future investment opportunity and not act on the basis of any matter contained in this Document. In providing this Document, the Company has not considered the objectives, financial position, taxation situation or other needs of any particular Recipient.

The distribution of this document in jurisdictions outside Australia may be restricted by law. Persons who come into possession of this document who are not in Australia, should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. In particular, this document does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States.

Financial data

All financial amounts contained in this presentation are expressed in Australian dollars (unless otherwise stated). Any discrepancies between totals and sums of components in tables, figures and body content contained in this presentation are due to rounding. Tables, figures and body content contained in this presentation have not been amended by ALC to correct immaterial summation differences that may arise from this rounding convention.

Investors should also be aware that certain financial data included in this presentation including underlying NPAT and underlying EBIT/EBITDA and measures described as "pro-forma", are "non-IFRS financial information" under ASIC regulatory Guide 230 (disclosing non-IFRS financial information). The non-IFRS financial information financial measures do not have a standardised meaning prescribed by Australian International Reporting Standards (AIFRS) and, therefore, may not be comparable to similarly titled measures presented by other companies, nor should they be construed as an alternative to other measures determined in accordance with AIFRS. Investors are cautioned, therefore, not to place undue reliance on any non-IFRS financial measures included in this presentation.

ALCIDION

01.

Snapshot

Company Overview

ALCIDION

A leading global health informatics platform modernising legacy health systems at scale

Global health informatics platform
enhancing and replacing outdated, manual and legacy systems
to meet modern day demands in healthcare.

Flagship product, Miya Precision –
delivering real-time, intuitive, clinical decision support,
AI enablement layer for safer delivery of care, clinical workflow
and much needed operational efficiencies.

Solving systemic problems in healthcare delivery –
fragmented data, clinician workload pressures, operational
inefficiencies and lack of system-wide operational insight.

100+
Healthcare Clients
transforming healthcare with Alcidion across more than 50,000 beds

130k+
Active Users
across Miya Precision and Smartpage

1B+
Observations Recorded
electronically at the point of care

25M+
Alerts Generated
to highlight patient deterioration

12%
Decrease in LoS
independently validated benefits

$1B+
Annual Impact
on the global healthcare economy

Investment Highlights

ALCIDION

Significant sales momentum following a record H1 FY26 and a defined and executable growth strategy across both current and new markets

Mission-critical health informatics platform providing a system of record and AI engagement layer for enterprise healthcare systems

Diversified and long-term recurring revenue underpinned by multi year contracts

Attractive unit economics with 80%+ gross margin

Capital light business model with negligible capex

Defined growth drivers with a multi-focus approach to grow revenue via existing customer expansion, new customer wins, new markets and geographies

Structural tailwinds given digitisation of healthcare & rising interest in AI to safely meet rising demands of clinicians, administrators and patient safety

FY26 forecast revenue of $50m+

Net Cash $15.1M, no debt as of 31 March 2026

Strong Global Footprint

ALCIDION

Growing global operations diversified across attractive target markets



Global footprint across the UK, Australia and NZ.

100+ clinical system implementations.

A platform approach to modernising healthcare assets and transforming the clinician experience.

Prospective Territories

FY26 – Financial guidance Snapshot

Growth across key financial metrics

$50M+
FY26 revenue guidance

Up min 23%+ on pcp[1]

Driven by several contract wins and expansions

$31.1M
ARR[2] (as at 31 Dec-25)

Will increase following UHSussex and Kyra products acquisition

Increasing recurring revenue base underpinned by long-term contracts

$70M+
FY26 YTD new & renewal TCV (as of Q3 + UHSussex)

$5.0M+
FY26 EBITDA guidance[3]

$5.8M
FY26 operating cashflow guidance

In-line with FY25

$15.1M cash, no debt as at 31 March 2026, will increase as at 30 June 2026

1. Comparisons are to prior corresponding period (FY25)
2. Annual Recurring Revenue defined as the value of Support & Maintenance (S&M), hosting and/or license revenue expected to be billed over the next 12 months. This does not include multi-year capital licenses paid during the year or which will reoccur again upon a future contract renewal. ARR is a measure of the future annualised revenue as at a point in time.
3. EBITDA: includes share-based payments and one-off restructure and M&A transaction costs

Our revenue model

Sustainable growth underpinned by long-term, contracted and high-quality recurring revenue

ALCIDION

Core Product

MIYA PRECISION Platform

Solutions

Patient Flow | Virtual Care | Integrated Care Record | Modern Modular EPR | Operations Centre | Clinical Workflow | Specialised Care

Revenue Streams	**Implementation &/or Services Fee**	**Capital License (Multi-year)**	**Annual subscription (License + M&S[1] + Hosting)**
Revenue Model	Upfront, one-off	Recurring (on contract renewal)	Recurring (Annually)
Nature of Contracts	• Required for any new customer • Typically, 10-15% of total contract value • Charged based on relevant contract project milestones • Implementation timeframe varies depending on solution; Patient Flow (3-6 months) vs. EPR (12-24 months)	• License fee recognised (& paid) upfront for multi-year period (typically 5-10 years) • Feature of larger UK NHS contracts due to the UK gov't funding structures • Reoccur on contract renewal (either as another capital license or bundled as an annual subscription)	• 3 - 10 year contract terms with renewal options • Capital licenses also include a M&S / hosting component • Most customers (excluding larger UK) often select annual subscription • Typically, billed qtr'ly or annual, in advance

1. Maintenance & Support

Revenue Dashboard

Sustainable growth underpinned by long-term, contracted and high-quality recurring revenue









ALCIDION

02.

Core Technology

Market Drivers

Modern clinician needs and improved patient outcomes driving the digitisation of outdated, legacy systems

Transition to digital

Shift towards digital within the healthcare sector to drive clinician effectiveness and reduce medical error

Operating efficiency and workflow

Smart bed allocation, reduced length of stay and real-time patient information in burdened health systems

Increasing demand for safe deployment of AI clinical solutions

Growing demand for safe AI enablement within patient records to support clinician workflows

Increasing industry support & funding

Increasing support and funding for digital solutions in the UK (through the NHS[1]) and in Australia

Need for improved healthcare workflow to deliver efficient and productive clinicians and safer patient outcomes

What is Miya Precision?

An unrivalled clinicial and administration platform

ALCIDION

Designed for AI

Miya Precision allows for AI enabling data consolidation to deliver insights to clinicians, whilst maintaining patient safety

Digital Clinical Workflow

Miya Precision enables clinicians to fully coordinate patient care, tasks, alerts and communication digitally

Operate in Real-Time

Systemwide transparency is available in real-time, showing bed availability, blockages, and critical events

MIYA PRECISION

Integrate and Liberate Data

Maximise the value of exiting Health IT investments

Intuitive User Interfaces

World leading visualisation and user experience

- Full Suite EPR/EMR
- Patient Administration
- Patient Flow
- Clinical Decision Support
- Clinical Communications
- Electronic Observations
- Data Interoperability
- System Wide Analytics

Smarter Solutions for Clinicians

Meeting the daily needs of clinicians, by clinicians

MIYA PRECISION BY ALCIDION

Powering Smarter Care

At the core of Alcidion's solutions is our FHIR-based interoperability platform for smarter decision support

Miya Precision Platform

- Data to FHIR
- Ontology Mapping
- CDS Engine

Solutions

Patient Flow & Command
Digitised clinical workflow & patient journey visualisation

Emergency
Emergency Department and Specialised Care

Modular EPR
Modular cloud-native EPR, PAS & AI enabled Noting

Virtual Care
Virtual care and remote patient management

Integrated Care Record
Longitudinal patient health record

Inpatient Solutions
EPR, PAS, Noting, Flow, Bed, Task and Results Mgmt

Outpatient Solutions
Appointment Mgmt, Clinical Mgmt, Documentation

Aged Care Flow
Integrated Care Record, Record Exchange, AI Enabled Intervention

Community & Mental Health
Integrated Care Record, Clinical Assessments and Documentation

Military Health
Integrated Care Record, IPS, Garrison/Deployed, Offline Operations

Markets

Miya Precision: An Orchestration layer &/or System of Record

ALCIDION

As AI agents are able to execute work autonomously, the SaaS layer is compressed with value shifting to the orchestration and trusted systems of record

Historically
The traditional 'SaaS' model

User (Admin, Clinician, Executives)

SaaS Layer - UI / Workflow / Integrations

System of record / data

Future
The 'SaaS' layer has been compressed

User (Admin, Clinician, Executives)

AI agent / orchestration layer – autonomous

SaaS Layer - compressed

System of record / data
Agents (AI) needs trusted data to act on

Miya Precision as the System of Record



- AI enablement
- Results Management
- Task Management
- Longitudinal Patient Record
- Patient Flow Management
- Virtual Care
- Predictive Analytics

- Clinical Record/CDR
- Patient Administration
- Master Patient Index
- Specialty Specific Systems



03.

Delivering Tangible Outcomes

ALCIDION

Case Study: Alfred Health

ALCIDION

Independent Study on Miya Precision Benefits

In 2023, Alfred Health introduced electronic patient journey boards (EPJBs) to 38 inpatient wards at The Alfred, Caufield and Sandringham hospitals. As part of the deployment, the Digital Health CRC & Monash University were engaged to conduct a study on the benefits of EPJBs. The study was conducted over 12 months capturing a series of baseline metrics to compare and evaluate impact.

1. Efficiency in bed allocation



Digital bed allocation decreased call duration by 67%, highlighting transparency, process simplification, capacity improvements and freeing up resources for additional tasks.

2. Reduction in outliers



The study identified a 17.7% reduction in the number of outliers at the point of admission, indicating improved availability of beds and visibility of both incoming patient demand and bed capacity in target wards.

3. Real-time patient information

100% Alignment of Patient Information FHIR-based two-way real-time integration eliminated a 25-40% discrepancy between EMR data and traditional whiteboards, enhancing patient safety and streamlining clinical updates.

4. Reductions in length of stay



During the course of the study, a consistent decline in patient length of stay (LoS) was observed, decreasing by 12.1% over an 18-month period from 3.15 days to 2.77 days.

5. Discharge planning improvement

100% of patient records now include an Estimated Date of Discharge (EDD), up from a baseline of 61%. Changes to EDDs require a reason, aiding analysis of discharge forecast accuracy and continuous improvement.

6. Consistency in ways of working

From 30 different ways of working

To 9 variations of EPJB tailored to the clinical workflow (with 80% commonality)

Further information can be found here: https://www.alcidion.com/news/an-independent-study-shows-the-ripple-effect-of-benefits-from-adopting-a-patient-flow-management-solution/

Case Studies

Driving real-world tangible outcomes

60 mins reduction in admin burden per clinician per shift South Tees Hospitals NHS Foundation Trust	76% Reduction in cardiac arrests NHS Fife	40% reduction in time to take observations Basildon and Thurrock University Hospitals
10% increase in patients processed in the ED within four hours Royal Darwin Hospital	£60K saved on paper annually Basildon and Thurrock University Hospitals	1 Minute Saved in the recording of each set of observations for every patient Canterbury and West Coast District Health Boards
15 minutes saved every hour, for every doctor Capital and Coast District	15 minutes training - intuitive, user-centred interface South Tees Hospitals NHS Foundation Trust	20 mins Physician reported time released per hour Manx Care, Lancashire Teaching Hospital, Guys & St Thomas
75% reduction in cardiac arrests Basildon and Thurrock University Hospitals	42% Reduction in medical errors Lancashire Teaching Hospital	75 minutes saved per Nursing Unit Manager every shift Royal Darwin Hospital

Miya Precision customers have been nominated for 6 prestigious awards at the 2026 HSJ Digital Awards

ALCIDION

Outstanding Achievement in EPR Implementation and Optimisation

"Clinical Excellence in the Digital Revolution: The Role of Miya in Safer, Smarter Care"

HSJ DIGITAL AWARDS

South Tees NHS Trust

Driving Virtual Wards and Hospital at Home Through Digital

"Transforming POSDU with a Virtual Ward: Accelerating Safe Patient Discharge"

HSJ DIGITAL AWARDS

South Tees NHS Trust

Digital Team of the Year

"Miya ED implementation at UHS"

HSJ DIGITAL AWARDS

University Hospitals Southampton (UHS)

Digital Transformation Organisation of the Year

"Transforming Care at South Tees: A Journey from Paper to Digital Excellence"

HSJ DIGITAL AWARDS

South Tees NHS Trust

Driving Prevention and Early Intervention through Digital

"University Hospitals Tees - Providing a Pathway of Support for the Most Vulnerable Patients"

HSJ DIGITAL AWARDS

South Tees NHS Trust

Improving Urgent and Emergency Care through Digital

"Miya ED implementation at UHS"

HSJ DIGITAL AWARDS

University Hospitals Southampton (UHS)

04.

FY26 – New customer wins and increasing share of wallet

Sales momentum accelerating...

ALCIDION

$140m+ of new and renewal TCV won over past 24 months
Average contract term 5-10 years

Jul 2024
Hume Rural Health
New customer
$4m / 5 yrs
Flow

Nov 2024
NALHN
New customer
$4.5m / 5 yrs
Flow

Feb 2025
Hywel Dda
New customer
$5.5m / 5 yrs
Flow

Sept 2025
North Cumbria NHS
Existing customer
$6.8m / 9.4 yrs
Expansion of EPR

Q2 FY26
Lanarkshire NHS
Existing Customer
3 yrs
Renewal-Patientrack

Mar 2026
Gold Coast Health
New customer
5 yrs
RPM / Virtual Care

Q3 FY26
Hywel Dda & South Tees
Existing customer
5 yrs
Miya ED

H1 FY25 | **H2 FY25** | **H1 FY26** | **H2 FY26**

Jul 2024
North Cumbria NHS
Existing customer
Est. $30-40m / 10 yrs
Preferred Supplier EPR

Nov 2024
Peninsula Health
New customer
$3.7m / 5 yrs
Flow

Feb 2025
North Cumbria NHS
Existing customer
~$39m / 10 yrs
Signed EPR

Q1 FY26
Bolton NHS
Existing customer
3 yrs
Renewal-Patientrack

Nov 2025
Leidos Aust (ADF)
Existing Customer
$12.3M / 2.7 yrs
Expanded capability

Jan 2026
UHSussex NHS
Existing Customer
Est. $35m+ / 7 yrs
Preferred Supplier EPR

May 2026
UHSussex NHS
Existing Customer
~$35m / 7 yrs
Signed EPR

May 2026
Acquired Kyra Flow products from Telstra Health (Aust)
Revenue $3.7M / 33 Customers

AUS UK

Notable FY26 New / Extension / Expansion Wins

ALCIDION

Continued ability to expand functionality with customers over time leading to TCV uplift

Leidos Australia / ADF (AUS)

leidos

Australian Government
Department of Defence

- 3rd expansion to the original contract to June 2028, with extension option out to 2036
- Continues to demonstrate depth and breadth of the Miya Precision platform across a variety of care environments, includes medications management
- ARR now exceeds $5.5m, underpins long-term financial stability of the business

North Cumbria NHS Trust (UK)

NHS
North Cumbria Integrated Care
NHS Foundation Trust

- Expanded to include third-party partner, Mizaic
- Mizaic (product, MediViewer) to provide electronic document management system (or EDMS)
- Including recent expansion, total TCV exceeds $45m over 10 years
- Implementation progressing on schedule & expected to be finalised in early in FY27.

Gold Coast Health (AUS)

Gold Coast Health
always care

- New 5-year contract to provide an end-to-end remote patient monitoring (RPM) solution
- Initial entry into Gold Coast, a digitally progressive health care organisation
- First deployment of Miya Precision in Queensland, an underrepresented state for Alcidion

Hywel Dda + South Tees NHS (UK)

GIG CYMRU NHS WALES
Bwrdd Iechyd Hywel Dda Health Board

NHS
South Tees Hospitals
NHS Foundation Trust

- Expanded existing relationships via deployment of Miya Emergency (Miya ED) modules
- Further evidence of land and expand strategy
- Validates ALC ability to develop and successfully commercialise new modules

Further EPR Validation: UHSussex

ALCIDION

In May 2026, signed contract with University Hospitals Sussex for new EPR platform solution

Contract Terms

7 years
Minimum Contract duration

A$35.0M
Total Contract Value (TCV)

Potential to add further modules over time

EPR Contract - Overview

- Selected following a competitive tender process
- Deploy Miya Precision core modules and Better medications management - provides clinicians real-time access to patient records while streamlining patient flow & improving clinical decision-making
- UHSx is an existing Alcidion customer utilising Patientrack for Observations and Assessments
- Deployment commenced in May 2026, expected to run for 18+ months

Traction in UK EPR Market

- 3rd UK EPR contract underpinning our growing referenceabilty
  - North Cumbria – 10 years, $45m+ TCV won via competive tender
  - South Tees - 10 years, $23m+ TCV with upside for additional modules
- Strategic location of EPR customers coupled with other Alcidion customers provide opportunity for future expansion across other Trusts within regions (ICB)

UHSussex - Overview

NHS
University Hospitals Sussex
NHS Foundation Trust

- One of the largest acute trusts in the UK
- Hospital & community care provided across 7 hospitals with more than 1.5 million outpatient appointments, A&E visits and surgery cases

Successful Deployments in H1 FY26

ALCIDION

Product Implementation delivery have always been a strength for Alcidion

NHS University Hospital Southampton NHS Foundation Trust

University Hospitals Southampton (UK)

- Deployed Miya Emergency – second customer to deploy module and first to replace existing ED digital system
- During 1st week of operations, UHS saw record patient intake, at one point able to efficiently manage 200+ concurrent patients in ED
- Creating more than 5000 documents per day

Government of South Australia Health Northern Adelaide Local Health Network

North Adelaide Local Health Network (AUS)

- In Q1 FY26, 'live' with Miya Flow, Access and Command modules.
- Electronic journey boards replaced whiteboards across multiple hospitals
- Bed management and operations centre capabilities 'live' at NALHN Network Operations Centre

GIG CYMRU NHS WALES Bwrdd Iechyd Hywel Dda Health Board

Hywel Dda Health Board (UK, Wales)

- In Q2 FY26, went live at Hywel Dda with Miya Flow & Observations and Assessments modules.
- First site in Wales
- Success at Hywel Dda positions Alcidion well for further opportunities in this market

NHS North Cumbria Integrated Care NHS Foundation Trust

North Cumbria NHS Trust (UK)

- Implementation progressing on schedule & expected to be finalised in early in FY27
- Given modular nature Miya Precision – key feature of Miya offering – customer will realise tangible benefits early in the roll-out.

Land and Expand Strategy Driving TCV Uplift

ALCIDION

Delivering tangible examples of strategy execution…

1 — Leidos Australia (Aus)

- **Q2’22** – 6-year contract to deliver Longitudinal Health Record for ADF
- **Q2’23** – Patientrack and other environments
- **Q2’26** – expanded module capability

2 — North Cumbria (UK)

- **Q3’25** – 10-year contract for EPR solution (several Miya modules)
- **Q4’25** – clinical comms module
- **Q1’26** – 3rd party contract w/ Mizaic
- **Q3’26** – non-clinical comms module

3 — South Tees (UK)

- **Q2’20** – 5-year contract for several Miya modules
- **Q2’20** – module expansion
- **Q2’23** – extended further 8 yrs with options for additional modules
- **Q3’26** – expanded to include Miya ED

4 — Hume (Aus)

- **Q1’25** – New contract covering 15 hospitals across Hume region of Vic, Australia
- **Q4’25** – expanded to include additional hospital sites

Illustrative (TCV) example of progressive module sales; unique ability to accommodate customers budget and requirements



ALCIDION

05.

Strategic Acquisition, Kyra Flow products

Acquired Kyra Flow products, from Telstra Health

ALCIDION

Highly complementary to Alcidion core business

Consolidates market position in ANZ market

Builds recurring revenue whilst being earnings accretive

Future opportunities for Miya Precision & Kyra customers

Attractive acquisition multiple

ALCIDION

06.

Growth Strategy and Outlook

Growth Pillars Support a Global Platform

ALCIDION

Multi-focus approach combining growth within existing customers, expansion in existing territories and attractive new markets and geographies

Organic Growth

1 Scale Existing Markets

- UK investment in next stage of NHS digitalisation – analog to digital
- Continued NHS investment in EPR's
- Expansion into more UK territories – Wales, Ireland, Scotland
- Expansion of Flow contracts in ANZ (supported by recent successes)
- Enabling move to virtual care

2 Evolve Product Functionality & Adjacencies

- Deepen AI capabilities across platform data
- Expand further into new modules of Care:
  - Virtual care & remote patient monitoring
  - Aged Care connectivity
  - Community Care – key part of reducing hospital flow & bed blockage

3 Expand into New Geographies

Priority Targets / Discussions commenced

- Canada
- Saudi Arabia / UAE
- SE Asia

4 M&A (Buy & Build)

- Expanding market share or product capabilities, ensuring acquisitions are EBITDA accretive (financially disciplined and measured approach to M&A)
- Expand into new geographies
- Expand outside acute / hospital setting

Outlook & Guidance

ALCIDION

Momentum continuing into 2H FY26 underpinned by preferred supplier status, high contracted revenue and a maturing pipeline of expansion & new opportunities

Outlook

- As of 31 Dec-25, contracted & renewal revenue to be recognised in FY26 of $43.1M (excludes any expected revenue contribution from UHSussex or new sales in H2)
- Selected as preferred supplier for UHSussex new EPR platform. Whilst contract negotiations remain ongoing, anticipate a contract structure with an upfront license fee payment shortly after signing. The contract is expected to be signed by mid Q4 FY26.
- Given several material contract wins and with a clear focus on accelerating new sales in both existing & new markets, the Company is incrementally investing in key areas of product delivery, sales and marketing to support deployment capability and pipeline conversion

FY26 Guidance (underpinned by the Outlook)

- Revenue expected to exceed $50.0M with EBITDA in excess of $5.0M; and
- Operating cashflow to remain positive in-line with FY25 operating cashflow of $5.8M

Growth strategy across several key pillars:

- Scale in existing markets - leveraging increased referenceabilty;
- Evolve product functionality & market adjacencies - deepening AI capability and entry into new models of care;
- Geographical expansion (Canada, Saudi Arabia & UAE) - early progress with procurement discussions underway in Canada and appointment of Middle East reseller partner/s is imminent; and
- Assess potential M&A opportunities

Investment Highlights

ALCIDION

Large Addressable Market

- Strong foothold within approximately 1/3rd of UK NHS acute Trusts using at least one ALC module
- Focus on management of patient flow creating increasing opportunities in ANZ
- Global opportunity in virtual care setting and remote patient monitoring
- Geographical expansion

Attractive Financial Profile

- $50M+ FY26 revenue guidance
- $31.1m ARR (as of 31 Dec-25) underpinned by multi-year (typically 3-10 year) contracts
- Gross profit margins 80%+
- Scale and operating leverage emerging - FY26 EBITDA guidance of $5.0M+
- FY26 Operating cashflow guidance of $5.8M

Marquee Customers

- $45.0M+ over 10 years with North Cumbria NHS for Miya Precision to deliver new EPR
- $40M+ with Leidos to assist Australian Defence Force (ADF) with health record
- $35m over 7 years with UHSussex NHS for Miya Precision to deliver new EPR
- $23.0M over 10 years (to 2033) with South Tees NHS (UK) for full Miya Precision suite

Product Offering

- Cloud native platform improving hospital efficiencies and clinical decision-making
- Highly interoperable and built on open standards
- AI enablement layer for healthcare
- Designed to be an active participant in health care rather than passive data store

Long-term Contracts

- Long-term customer contracts (typically 5-10 years) with ongoing options for renewal
- Critical nature of software results in negligible churn
- Enterprise healthcare organisations (NHS Trusts, State health, private health)

Market Tailwinds

- Health systems stretched with limited bed availability & under-resourced clinical staff seeking improved tech solutions for efficiency
- Governments committed to their pursuit of modernising the systems with significant funding being allocated

07.

Appendix

Corporate Snapshot

ALCIDION

ASX:ALC Trading Information

Share Price (18 June 2026)	$0.100
12-month Low / High	$0.082 - $0.145
12-month average daily liquidity ($)	$215k
Shares outstanding	1,343M
Market Cap	$134M
Cash (31 March 2026)	$15.1M
Debt (31 March 2026)	Nil
Enterprise Value	$119M
EV / FY26 Revenue (guidance)	2.4x
Institutional Shareholders	~25%
Founders & Management	~21%

ASX:ALC Share Price History



Alcidion Board – Deep Healthtech Expertise

ALCIDION

Rebecca Wilson

Non-executive Chair

Experienced company director with private, ASX-listed and not-for-profit organisations. Rebecca has held global leadership roles in marketing communication, investor relations, and corporate affairs. She has deep expertise in ESG, complex stakeholder communication, issues, crisis and risk management, transactions, and investor relations.

Rebecca is currently the Chair of Clever Culture Systems Limited (ASX:CC5), NED of Hansen Technologies (ASX HSN) and Vitura Health Limited (ASX: VIT).

Kate Quirke

Group Managing Director/ Chief Executive Officer

25+ years of digital health sector experience. Kate has held leading management roles at large healthcare software firms, which has included large procurements and implementations of healthcare information technology across Australia, New Zealand, the United Kingdom and South-East Asia.

Daniel Sharp

Non-executive Director

25 years+ senior executive experience in investment banking and corporate finance. Daniel was previously Executive Director of Corporate Finance at Canaccord Genuity where he led dozens of IPOs, equity capital market transactions and corporate finance advisory projects across the healthcare, life sciences, technologies, financial services and general industrials sectors.

Danny is currently a NED of Botanix Pharmaceuticals (ASX: BOT), and NED of Cyban Pty Ltd.

Andrew Way

Non-executive Director

35+ years experience in senior healthcare leadership roles across both Australian and UK markets.

Andrew has been a Chief Executive for nearly 25 years, most recently as the CEO of Alfred Health in Melbourne, Victoria, finishing in 2024. Andrew has led several hospitals through major clinical and non-clinical digital transformations. Awarded an AM for his services in support of clinical research and leadership.

Andrew is currently Board Chair of HealthShare Victoria and a Director of Australian College of Health Service Management (ACHSM).

William Smart

Non-executive Director

Global digital health leader with 30+ years of experience leading transformational change in complex organisations. Based in the UK, Will is currently Digital NED, Great Western Hospitals NHS Foundation He has held executive roles in several NHS Trusts including as Group Chief Information Officer, Royal Free London NHS Foundation Trust. Until recently,

Will served as the Global Director of External Relations, Dedalus Group where he had responsibilities across the UK and Europe and led the launch of its European built Electronic Patient Record (EPR) solution into Ireland and the UK.

ALCIDION